Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: THY121
MIFTS: 66

Thyroid Gland Anaplastic Carcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Thyroid Gland Anaplastic Carcinoma

About this section

MalaCards integrated aliases for Thyroid Gland Anaplastic Carcinoma:

Name: Thyroid Gland Anaplastic Carcinoma 12 15
Anaplastic Thyroid Carcinoma 12 52 58
Anaplastic Thyroid Cancer 74 52
Thyroid Carcinoma, Anaplastic 52
Thyroid Carcinoma Anaplastic 54
Thyroid Cancer, Anaplastic 52

Characteristics:

Orphanet epidemiological data:

58
anaplastic thyroid carcinoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare endocrine diseases


External Ids:

Disease Ontology 12 DOID:0080522
NCIt 49 C3878
MESH via Orphanet 44 C536910
ICD10 via Orphanet 33 C73
UMLS via Orphanet 72 C0238461
Orphanet 58 ORPHA142
Sources

Summaries for Thyroid Gland Anaplastic Carcinoma

About this section
NIH Rare Diseases : 52 Anaplastic thyroid cancer (ATC) accounts for less than 2% of all thyroid cancers and is the most aggressive type of thyroid cancer. Most cases of anaplastic thyroid cancer are diagnosed in the sixth to seventh decade of life. Women are more likely to be affected than men. ATC generally occurs in individuals with a history of goiter or thyroid cancer. A history of head and neck radiation or exposure to radioactive materials may also increase the risk for ATC. Patients with ATC generally present with a rapidly-growing neck mass which may cause trouble swallowing (dysphagia ), coughing, neck pain, and trouble breathing (dyspnea). Metastasis is present in more than half of individuals at the time of diagnosis. Patients with metastases may also present with bone pain, lymph node enlargement, weakness, and neurological deficits. Treatment of ATC is mostly palliative .

MalaCards based summary : Thyroid Gland Anaplastic Carcinoma, also known as anaplastic thyroid carcinoma, is related to thyroid carcinoma and differentiated thyroid carcinoma. An important gene associated with Thyroid Gland Anaplastic Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Development HGF signaling pathway. The drugs Pemetrexed and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and bone, and related phenotypes are anaplastic thyroid carcinoma and broad neck

Disease Ontology : 12 A thyroid gland carcinoma that is composed of undifferentiated cells.

Wikipedia : 74 Anaplastic thyroid cancer (ATC), also known as anaplastic thyroid carcinoma, is an aggressive form of... more...

Sources

Related Diseases for Thyroid Gland Anaplastic Carcinoma

About this section

Diseases related to Thyroid Gland Anaplastic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 382)
# Related Disease Score Top Affiliating Genes
1 thyroid carcinoma 32.7 TSHR TPO TG RET PTEN PIK3CA
2 differentiated thyroid carcinoma 32.0 TSHR TPO TP53 TG RET PAX8
3 thyroid tumor 31.8 TPO TP53 TG RET PTEN PIK3CA
4 papillary carcinoma 31.7 TSHR TPO TG RET PAX8 NKX2-1
5 thyroiditis 31.6 TSHR TPO TG RET NKX2-1 CALCA
6 graves disease 1 31.5 TSHR TPO TG CALCA
7 multinodular goiter 31.4 TSHR TPO TG RET PAX8 NKX2-1
8 thyroid lymphoma 31.4 TPO TP53 TG CALCA
9 adenoma 31.3 TSHR TP53 TG RET PIK3CA CDH1
10 endemic goiter 31.3 TSHR TPO TG CALCA
11 thyroid cancer, nonmedullary, 2 31.3 TSHR TG PTEN PAX8 CALCA BRAF
12 hyperthyroidism 31.3 TSHR TPO TG CALCA
13 nodular goiter 31.2 TSHR TPO TG RET CALCA BRAF
14 graves' disease 31.2 TSHR TPO TG PAX8
15 thyroid gland medullary carcinoma 31.2 TG RET PAX8 CALCA
16 hypothyroidism 31.2 TSHR TPO TG RET PAX8 NKX2-1
17 thyroid carcinoma, familial medullary 31.1 TG RET NKX2-1 CALCA BRAF
18 substernal goiter 31.1 TG CALCA
19 acute thyroiditis 31.0 TPO TG CALCA
20 neuroblastoma 31.0 TP53 RET PTEN PIK3CA MIR17 CDKN1A
21 papillary adenocarcinoma 31.0 TP53 NKX2-1 MIR30A CDH1
22 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.0 TSHR TPO TG
23 goiter 31.0 TSHR TPO TG RET PAX8 NKX2-1
24 subacute thyroiditis 31.0 TSHR TPO TG
25 exophthalmos 30.9 TSHR TPO TG
26 follicular adenoma 30.9 TSHR TPO TG RET PTEN PAX8
27 endocrine gland cancer 30.9 RET MIR34C MIR30A MIR18A MIR17
28 papillary thyroid microcarcinoma 30.9 TSHR TG NKX2-1 CALCA BRAF
29 melanoma 30.9 TP53 PTEN PIK3CA MIR34C MIR19A MIR17
30 cowden syndrome 30.9 TP53 RET PTEN PIK3CA MIR19A
31 leukemia, chronic myeloid 30.9 TP53 PTEN MIR19A MIR18A MIR17 CDKN1A
32 oral squamous cell carcinoma 30.9 TP53 PTEN MIR34C MIR30D MIR19A MIR17
33 endometrial cancer 30.9 TP53 RET PTEN PIK3CA PAX8 NKX2-1
34 lynch syndrome 30.9 TP53 PTEN PIK3CA MIR17 CDH1 BRAF
35 kidney cancer 30.8 TP53 PTEN PIK3CA MIR17 CDKN1A
36 gastrointestinal stromal tumor 30.8 TP53 PTEN CDKN1A CDH1 BRAF
37 thyroid gland cancer 30.8 TSHR TPO TP53 TG RET PTEN
38 lung cancer susceptibility 3 30.8 TP53 RET PTEN PIK3CA NKX2-1 MIR30D
39 leukemia, chronic lymphocytic 30.8 TP53 PTEN PIK3CA MIR30D MIR30A MIR19A
40 thyroid gland disease 30.7 TSHR TPO TG RET PAX8 NKX2-1
41 brain cancer 30.7 TP53 PTEN PIK3CA MIR34C MIR19A MIR18A
42 adenocarcinoma 30.7 TP53 RET PTEN PIK3CA NKX2-1 CDKN1A
43 squamous cell carcinoma, head and neck 30.7 TP53 PTEN PIK3CA MIR30A MIR19A MIR18A
44 medulloblastoma 30.6 TP53 RET PTEN PIK3CA MIR30D MIR19A
45 malignant pleural mesothelioma 30.5 TP53 NKX2-1 MIR17
46 lung cancer 30.4 TP53 RET PTEN PIK3CA NKX2-1 MIR34C
47 ovarian cancer 30.3 TP53 PTEN PIK3CA PAX8 MIR34C MIR30A
48 thyroid gland mucoepidermoid carcinoma 10.8 TG CALCA
49 malignant struma ovarii 10.8 TG RET NKX2-1
50 ovarian benign neoplasm 10.8 TP53 TG PAX8

Graphical network of the top 20 diseases related to Thyroid Gland Anaplastic Carcinoma:



Diseases related to Thyroid Gland Anaplastic Carcinoma
Sources

Symptoms & Phenotypes for Thyroid Gland Anaplastic Carcinoma

About this section

Human phenotypes related to Thyroid Gland Anaplastic Carcinoma:

58 31 (show all 24)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 anaplastic thyroid carcinoma 58 31 obligate (100%) Obligate (100%) HP:0011779
2 broad neck 58 31 hallmark (90%) Very frequent (99-80%) HP:0000475
3 hoarse voice 58 31 hallmark (90%) Very frequent (99-80%) HP:0001609
4 nodular goiter 58 31 hallmark (90%) Very frequent (99-80%) HP:0005994
5 dysphagia 58 31 frequent (33%) Frequent (79-30%) HP:0002015
6 neoplasm of the lung 58 31 frequent (33%) Frequent (79-30%) HP:0100526
7 vocal cord paralysis 58 31 frequent (33%) Frequent (79-30%) HP:0001605
8 lymphadenopathy 58 31 frequent (33%) Frequent (79-30%) HP:0002716
9 respiratory distress 58 31 frequent (33%) Frequent (79-30%) HP:0002098
10 upper airway obstruction 58 31 frequent (33%) Frequent (79-30%) HP:0002781
11 pain 58 31 frequent (33%) Frequent (79-30%) HP:0012531
12 laryngotracheal stenosis 58 31 frequent (33%) Frequent (79-30%) HP:0004894
13 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
14 cough 58 31 occasional (7.5%) Occasional (29-5%) HP:0012735
15 hemoptysis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002105
16 dysphonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001618
17 stridor 58 31 occasional (7.5%) Occasional (29-5%) HP:0010307
18 neoplasm of the skeletal system 58 31 occasional (7.5%) Occasional (29-5%) HP:0010622
19 abnormal skeletal muscle morphology 31 occasional (7.5%) HP:0011805
20 tracheoesophageal fistula 58 31 very rare (1%) Very rare (<4-1%) HP:0002575
21 malignant neoplasm of the central nervous system 58 31 very rare (1%) Very rare (<4-1%) HP:0100836
22 dyspnea 58 Occasional (29-5%)
23 goiter 58 Very frequent (99-80%)
24 abnormal muscle morphology 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Thyroid Gland Anaplastic Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.23 BRAF CDH1 CDKN1A NKX2-1 PAX8 PIK3CA
2 growth/size/body region MP:0005378 10.21 BRAF CDH1 CDKN1A NKX2-1 PAX8 PIK3CA
3 immune system MP:0005387 10.11 ADGRE5 BRAF CDH1 CDKN1A PIK3CA PTEN
4 digestive/alimentary MP:0005381 10.08 BRAF CDH1 CDKN1A NKX2-1 PTEN RET
5 limbs/digits/tail MP:0005371 9.97 BRAF CDKN1A PAX8 PTEN RET TG
6 neoplasm MP:0002006 9.91 BRAF CDH1 CDKN1A NKX2-1 PIK3CA PTEN
7 hearing/vestibular/ear MP:0005377 9.88 BRAF CDKN1A PAX8 TP53 TPO TSHR
8 no phenotypic analysis MP:0003012 9.76 ADGRE5 CDH1 CDKN1A NKX2-1 PAX8 PIK3CA
9 reproductive system MP:0005389 9.7 BRAF CDH1 CDKN1A NKX2-1 PAX8 PIK3CA
10 skeleton MP:0005390 9.32 BRAF CDKN1A NKX2-1 PAX8 PIK3CA PTEN
Sources

Drugs & Therapeutics for Thyroid Gland Anaplastic Carcinoma

About this section

Drugs for Thyroid Gland Anaplastic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pemetrexed Approved, Investigational Phase 2 137281-23-3, 150399-23-8 60843 446556
2
leucovorin Approved Phase 2 58-05-9 6006 143
3
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
4
Fluorouracil Approved Phase 2 51-21-8 3385
5
Hydroxyurea Approved Phase 2 127-07-1 3657
6
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
7
Sodium citrate Approved, Investigational Phase 2 68-04-2
8
Tamoxifen Approved Phase 2 10540-29-1 2733526
9
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
10
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
11
Cemiplimab Approved, Investigational Phase 2 1801342-60-8
12
tannic acid Approved Phase 2 1401-55-4
13
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
14
Vemurafenib Approved Phase 2 918504-65-1 23252090 42611257
15
Ipilimumab Approved Phase 2 477202-00-9
16
nivolumab Approved Phase 2 946414-94-4
17
Trametinib Approved Phase 2 871700-17-3 11707110
18
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
19
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
20
Pembrolizumab Approved Phase 2 1374853-91-4
21
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
22
Lenvatinib Approved, Investigational Phase 2 417716-92-8
23
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
24
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
25
Bevacizumab Approved, Investigational Phase 2 216974-75-3
26
Cisplatin Approved Phase 1, Phase 2 15663-27-1 2767 441203 84093
27
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
28
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
29
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
30 Molgramostim Investigational Phase 2 99283-10-0
31
Efatutazone Investigational Phase 2 223132-37-4
32 Vitamin B Complex Phase 2
33 Folic Acid Antagonists Phase 2
34 Folate Phase 2
35 Vitamin B9 Phase 2
36 Immunosuppressive Agents Phase 2
37 Antimetabolites Phase 2
38 Hormone Antagonists Phase 2
39 Citrate Phase 2
40 Antineoplastic Agents, Hormonal Phase 2
41 Estrogen Receptor Modulators Phase 2
42 Estrogen Antagonists Phase 2
43 Liver Extracts Phase 2
44 Estrogens Phase 2
45 Estrogen Receptor Antagonists Phase 2
46 Cola Phase 2
47 Anti-HIV Agents Phase 2
48 Vaccines Phase 2
49 Anti-Infective Agents Phase 2
50 Antiviral Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 61)
# Name Status NCT ID Phase Drugs
1 A Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin in Comparison With Paclitaxel and Carboplatin Against Anaplastic Thyroid Carcinoma [FACT] Terminated NCT00507429 Phase 2, Phase 3 CA4P;paclitaxel;carboplatin
2 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Fosbretabulin Tromethamine (CA4P) in Combination With Paclitaxel and Carboplatin in Anaplastic Thyroid Carcinoma (FACT2) Withdrawn NCT01701349 Phase 3 Fosbretabulin + paclitaxel + carboplatin;Placebo + paclitaxel + carboplatin
3 Prospective Study of Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer Unknown status NCT03565536 Phase 2 Nexavar
4 Phase 2 Trial of Pemetrexed (Alimtaâ„¢) Combined With Paclitaxel in Patients With Recurrent/Advanced Follicular, Papillary or Anaplastic Thyroid Cancer Unknown status NCT00786552 Phase 2 pemetrexed + paclitaxel
5 A Phase II Study to Investigate the Efficacy of RAD001 (Afinitor®, Everolimus) in Patients With Irresectable Recurrent or Metastatic Differentiated, Undifferentiated (Anaplastic) and Medullary Thyroid Carcinoma Unknown status NCT01118065 Phase 2 everolimus
6 Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Cancer Completed NCT00654238 Phase 2 sorafenib
7 A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer Completed NCT00603941 Phase 1, Phase 2 CS7017;Paclitaxel
8 Phase II Trial Of Combretastatin A-4 Phosphate (CA4P) In Advanced Anaplastic Carcinoma Of The Thyroid Completed NCT00060242 Phase 2 fosbretabulin disodium
9 Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer (HOPE) Completed NCT02726503 Phase 2 Lenvatinib
10 Phase 2 Study of Pembrolizumab Combined With Chemoradiation Therapy in Anaplastic Thyroid Cancer Completed NCT03211117 Phase 2 Docetaxel;Doxorubicin Hydrochloride
11 A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) Completed NCT01240590 Phase 1, Phase 2 Crolibulin;Cisplatin
12 A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer Completed NCT00625846 Phase 2 Pazopanib Hydrochloride
13 A Phase II Study of ZD 1839 (IRESSA®) in Patients With Advanced Thyroid Cancer Completed NCT00095836 Phase 2 Gefitinib
14 A Multi-center, Single-arm, Open-label Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Sorafenib in Japanese Patients With Anaplastic Thyroid Carcinoma or Locally Advanced or Metastatic Medullary Thyroid Carcinoma Completed NCT02114658 Phase 2 Sorafenib (Nexavar,BAY43-9006)
15 A Multicenter Phase II Study of Intensified Concomitant Chemoradiotherapy for Patients With Anaplastic Thyroid Cancer Completed NCT00004089 Phase 2 fluorouracil;hydroxyurea;paclitaxel
16 An Open Label Multi-Center Phase II Study of RAD001 in Advanced Thyroid Cancer Completed NCT01164176 Phase 2 everolimus
17 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
18 Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
19 A Pilot Study of the Addition of Cemiplimab, an Antibody to PD-1, to the Treatment of Subjects With BRAF-Mutant Anaplastic Thyroid Cancer Who Are No Longer Responding to Dabrafenib and Trametinib Recruiting NCT04238624 Phase 2 Dabrafenib;Trametinib
20 Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/ Undifferentiated Thyroid Cancer Recruiting NCT02688608 Phase 2 Pembrolizumab
21 A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer Recruiting NCT02244463 Phase 2 MLN0128
22 Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas Recruiting NCT03181100 Phase 2 Atezolizumab;Cobimetinib;Nab-paclitaxel;Paclitaxel;Vemurafenib
23 A Phase 2 Study of Nivolumab Plus Ipilimumab in RAI Refractory, Aggressive Thyroid Cancer With Exploratory Cohorts in Medullary and Anaplastic Thyroid Cancer Recruiting NCT03246958 Phase 2 Nivolumab;Ipilimumab
24 A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer Active, not recruiting NCT01236547 Phase 2 Paclitaxel;Pazopanib Hydrochloride
25 A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer Active, not recruiting NCT02152137 Phase 2 efatutazone;paclitaxel
26 Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies Active, not recruiting NCT02404441 Phase 1, Phase 2
27 A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting Active, not recruiting NCT02041260 Phase 2 Cabozantinib
28 A Phase II, Open-label, Study in Subjects With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib Active, not recruiting NCT02034110 Phase 2 Dabrafenib;Trametinib
29 AcSé CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug. Active, not recruiting NCT02034981 Phase 2 Crizotinib
30 Lenvatinib in Combination With Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer Not yet recruiting NCT04171622 Phase 2 Lenvatinib
31 Exploratory Basket Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. CABATEN Study Not yet recruiting NCT04400474 Phase 2 Cabozantinib 40 mg
32 An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) Terminated NCT02657369 Phase 2 Lenvatinib 24 mg
33 Phase 2 Study With Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer Terminated NCT00804830 Phase 2 Bevacizumab
34 Phase II Trial of BAY 43-9006 in Patients With Advanced Anaplastic Carcinoma of the Thyroid Terminated NCT00126568 Phase 2 sorafenib tosylate
35 Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma Terminated NCT00095693 Phase 2 sorafenib tosylate
36 Phase II Trial of Combined Modality Combretastatin A-4 Phosphate (CA4P)-Based Therapy for Patients With Newly Diagnosed Anaplastic Thyroid Cancer [Induction Chemotherapy With Doxorubicin/Cisplatin; Combined Modality Therapy With CA4P and Radiation; Followed by 2 Cycles of CA4P Consolidation] Terminated NCT00077103 Phase 1, Phase 2 cisplatin;doxorubicin hydrochloride;fosbretabulin disodium
37 Phase II Trial Evaluating Gleevec (Imatinib Mesylate Formerly Known as STI571) in Patients With Anaplastic Thyroid Cancer Terminated NCT00115739 Phase 2 Imatinib
38 A Phase II Trial of CUDC-907 in Patients With Metastatic and Locally Advanced Thyroid Cancer Terminated NCT03002623 Phase 2 CUDC-907
39 A Phase I/IIa Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced, Unresectable Solid Tumors Terminated NCT02012231 Phase 1, Phase 2 PLX8394
40 Ceritinib in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer Withdrawn NCT02289144 Phase 2 Ceritinib
41 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
42 Phase I Trial of NGR-TNF Administered Every 3 Weeks as a 1 Hour Intravenous Infusion in Patients With Solid Tumor Completed NCT00098943 Phase 1
43 A Phase I Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 and Paclitaxel in Recurrent or Metastatic Carcinoma of the Head and Neck Completed NCT00005647 Phase 1 paclitaxel;semaxanib
44 A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer Completed NCT00005842 Phase 1 tipifarnib
45 B-Uptake In Different Tumours Using The Boron Compounds BSH And BPA Completed NCT00062348 Phase 1 boronophenylalanine-fructose complex;sodium borocaptate
46 First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-Driven Advanced Solid Tumors Recruiting NCT04429542 Phase 1 BCA101;Pembrolizumab
47 A Pilot Study of Durvalumab (MEDI4736) With Tremelimumab in Combination With Image Guided Stereotactic Body Radiotherapy (SBRT) in the Treatment of Metastatic Anaplastic Thyroid Cancer Active, not recruiting NCT03122496 Phase 1 durvalumab;tremelimumab
48 A Phase I Trial of Concurrent Intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF Mutated Anaplastic Thyroid Cancer Not yet recruiting NCT03975231 Phase 1 Dabrafenib;Trametinib
49 A Multi Center Phase I Study of AIC100 in Relapsed and/or Refractory Advanced Thyroid Cancer and Anaplastic Thyroid Cancer Not yet recruiting NCT04420754 Phase 1
50 A Phase I Trial Assessing Adalimumab (Humira®), a Tumor Necrosis Factor α Inhibitor Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers Withdrawn NCT02516774 Phase 1 Adalimumab

Search NIH Clinical Center for Thyroid Gland Anaplastic Carcinoma

Sources

Genetic Tests for Thyroid Gland Anaplastic Carcinoma

About this section
Sources

Anatomical Context for Thyroid Gland Anaplastic Carcinoma

About this section

MalaCards organs/tissues related to Thyroid Gland Anaplastic Carcinoma:

40
Thyroid, Lymph Node, Bone, Lung, Endothelial, Skeletal Muscle, Liver
Sources

Publications for Thyroid Gland Anaplastic Carcinoma

About this section

Articles related to Thyroid Gland Anaplastic Carcinoma:

(show top 50) (show all 1172)
# Title Authors PMID Year
1
Hsa-miR-34c suppresses growth and invasion of human laryngeal carcinoma cells via targeting c-Met. 46
20198305 2010
2
Wild-type p53 enhances the cytotoxic effect of radionuclide gene therapy using sodium iodide symporter in a murine anaplastic thyroid cancer model. 61 54
19727716 2010
3
R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-kappaB pathway. 54 61
19230027 2009
4
Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner. 61 54
18509005 2008
5
Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. 46
18429962 2008
6
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. 61 54
18458053 2008
7
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. 61 54
18000091 2008
8
Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. 46
17563749 2007
9
Quantitative measurement of telomerase reverse transcriptase, thyroglobulin and thyroid transcription factor 1 mRNAs in anaplastic thyroid carcinoma tissues and cell lines. 61 54
17671725 2007
10
Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. 61 54
17327374 2007
11
Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. 54 61
16899627 2006
12
Ribonucleic acid interference targeting S100A4 (Mts1) suppresses tumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model. 61 54
16551737 2006
13
Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. 54 61
16647341 2006
14
Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. 61 54
16331265 2006
15
BRAF is a therapeutic target in aggressive thyroid carcinoma. 54 61
16533790 2006
16
Altered gene expression profiles by sodium/iodide symporter gene transfection in a human anaplastic thyroid carcinoma cell line using a radioactive complementary DNA microarray. 61 54
16264365 2005
17
Differential effects of TGF-beta1 on telomerase activity in thyroid carcinoma cell lines. 54 61
16288728 2005
18
Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma. 54 61
16278386 2005
19
RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. 61 54
15980887 2005
20
Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene. 54 61
16029487 2005
21
Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. 61 54
15880523 2005
22
Modulation of retrovirally driven therapeutic genes by mutant TP53 in anaplastic thyroid carcinoma. 61 54
15650765 2005
23
BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. 61 54
15195111 2004
24
Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic thyroid carcinoma. 54 61
14654945 2004
25
[Genetic causes of the thyroid carcinomas]. 54 61
15584614 2004
26
Gadd45gamma expression is reduced in anaplastic thyroid cancer and its reexpression results in apoptosis. 61 54
12915687 2003
27
Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. 61 54
12843138 2003
28
Interference with TGF-beta1 and -beta3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma. 61 54
12432546 2002
29
Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells. 54 61
12495476 2002
30
Multistep carcinogenesis in anaplastic thyroid carcinoma: a case report. 61 54
11902457 2002
31
Apoptosis: life through planned cellular death regulating mechanisms, control systems, and relations with thyroid diseases. 61 54
11838727 2002
32
BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1). 54 61
11453659 2001
33
Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. 61 54
10942601 2000
34
N-cadherin-mediated adhesion and aberrant catenin expression in anaplastic thyroid-carcinoma cell lines. 54 61
10521809 1999
35
Lack of responsiveness to TGF-beta1 in a thyroid carcinoma cell line with functional type I and type II TGF-beta receptors and Smad proteins, suggests a novel mechanism for TGF-beta insensitivity in carcinoma cells. 61 54
10459856 1999
36
Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. 54 61
10213482 1999
37
Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line. 61 54
9768682 1998
38
p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. 61 54
9038381 1997
39
Decreased growth rate and tumour formation of human anaplastic thyroid carcinoma cells transfected with a human thyrotropin receptor cDNA in NMRI nude mice treated with propylthiouracil. 54 61
8892315 1996
40
Thyroid anaplastic carcinoma producing granulocyte-colony-stimulating factor and parathyroid hormone-related protein. 61 54
7549149 1995
41
Nuclear accumulation of MDM2 protein in well-differentiated papillary thyroid carcinomas. 61 54
8612724 1995
42
Expression of multidrug resistance-associated protein (MRP) in anaplastic carcinoma of the thyroid. 61 54
8050090 1994
43
p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. 54 61
1483945 1992
44
The molecular biology of the human anaplastic thyroid carcinoma cell. 61 54
1726928 1991
45
Anaplastic thyroid carcinoma. Immunocytochemical study of 32 cases. 61 54
1712540 1991
46
Anaplastic thyroid carcinoma: a nationwide cohort study on incidence, treatment and survival in the Netherlands over 3 decades. 61
32460234 2020
47
Re: "Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma" by Wang et al. 61
32397830 2020
48
Immunotherapy for Anaplastic Thyroid Carcinoma. 61
32552275 2020
49
Anaplastic thyroid carcinoma with rhabdoid phenotype: An unusual case and a comprehensive review. 61
32515545 2020
50
Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma. 61
32292131 2020
Sources

Variations for Thyroid Gland Anaplastic Carcinoma

About this section

ClinVar genetic disease variations for Thyroid Gland Anaplastic Carcinoma:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802

Cosmic variations for Thyroid Gland Anaplastic Carcinoma:

9 (show top 50) (show all 5257)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM90416635 ZNF703 thyroid,NS,carcinoma,anaplastic carcinoma c.1232C>T p.A411V 8:37698133-37698133 30
2 COSM101980343 XPO1 thyroid,NS,carcinoma,anaplastic carcinoma c.1353A>G p.I451M 2:61492946-61492946 30
3 COSM88298168 VHL thyroid,NS,carcinoma,anaplastic carcinoma c.289C>T p.P97S 3:10142136-10142136 30
4 COSM85196814 U2AF1 thyroid,NS,carcinoma,anaplastic carcinoma c.247G>C p.E83Q 21:43095696-43095696 30
5 COSM85193419 U2AF1 thyroid,NS,carcinoma,anaplastic carcinoma c.297G>A p.M99I 21:43095489-43095489 30
6 COSM86824282 TYRO3 thyroid,NS,carcinoma,anaplastic carcinoma c.2194C>T p.P732S 15:41573727-41573727 30
7 COSM131092631 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1672G>A p.V558M 14:81143730-81143730 30
8 COSM131089965 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1911G>T p.M637I 14:81143969-81143969 30
9 COSM131087195 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.842G>C p.S281T 14:81139828-81139828 30
10 COSM131089960 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1898A>C p.D633A 14:81143956-81143956 30
11 COSM131083598 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1703T>C p.I568T 14:81143761-81143761 30
12 COSM131084149 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1789G>C p.V597L 14:81143847-81143847 30
13 COSM131083592 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1514G>A p.S505N 14:81143572-81143572 30
14 COSM87033564 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.1439A>G p.Y480C 16:2063049-2063049 30
15 COSM87027114 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.229G>A p.A77T 16:2053345-2053345 30
16 COSM87027138 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.5113G>A p.D1705N 16:2088092-2088092 30
17 COSM87050085 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.793G>T p.G265C 16:2057123-2057123 30
18 COSM85724074 TSC1 thyroid,NS,carcinoma,anaplastic carcinoma c.2293C>T p.Q765* 9:132902703-132902703 30
19 COSM85721651 TSC1 thyroid,NS,carcinoma,anaplastic carcinoma c.1444A>G p.I482V 9:132906134-132906134 30
20 COSM94326844 TRRAP thyroid,NS,carcinoma,anaplastic carcinoma c.3073G>A p.A1025T 7:98927264-98927264 30
21 COSM94314937 TRRAP thyroid,NS,carcinoma,anaplastic carcinoma c.6611G>A p.G2204E 7:98961403-98961403 30
22 COSM88645132 TP63 thyroid,NS,carcinoma,anaplastic carcinoma c.503A>G p.N168S 3:189808450-189808450 30
23 COSM88668202 TP63 thyroid,NS,carcinoma,anaplastic carcinoma c.1161G>C p.M387I 3:189869355-189869355 30
24 COSM88654263 TP63 thyroid,NS,carcinoma,anaplastic carcinoma c.288C>G p.I96M 3:189738738-189738738 30
25 COSM87906063 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.451C>A p.P151T 17:7675161-7675161 30
26 COSM87899067 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.838A>G p.R280G 17:7673782-7673782 30
27 COSM87899695 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.715A>G p.N239D 17:7674248-7674248 30
28 COSM87902009 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.737T>A p.M246K 17:7674226-7674226 30
29 COSM87910495 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.832C>T p.P278S 17:7673788-7673788 30
30 COSM87897745 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.524G>A p.R175H 17:7675088-7675088 30
31 COSM87912901 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.376-2A>G p.? 17:7675238-7675238 30
32 COSM87967006 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.919+1G>C p.? 17:7673700-7673700 30
33 COSM87900157 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.818G>T p.R273L 17:7673802-7673802 30
34 COSM87903105 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.853G>T p.E285* 17:7673767-7673767 30
35 COSM88211130 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.75-1G>A p.? 17:7676404-7676404 30
36 COSM87949172 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.695T>A p.I232N 17:7674268-7674268 30
37 COSM87935416 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.499C>T p.Q167* 17:7675113-7675113 30
38 COSM87904420 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.514G>T p.V172F 17:7675098-7675098 30
39 COSM87950227 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.607G>T p.V203L 17:7674924-7674924 30
40 COSM87898758 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.707A>G p.Y236C 17:7674256-7674256 30
41 COSM87910752 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.949C>T p.Q317* 17:7673579-7673579 30
42 COSM87900980 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.839G>A p.R280K 17:7673781-7673781 30
43 COSM87905748 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.404G>A p.C135Y 17:7675208-7675208 30
44 COSM88277919 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.858A>T p.E286D 17:7673762-7673762 30
45 COSM87898463 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.733G>T p.G245C 17:7674230-7674230 30
46 COSM87902864 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.641A>G p.H214R 17:7674890-7674890 30
47 COSM87902369 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.1009C>T p.R337C 17:7670700-7670700 30
48 COSM87913984 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.800G>C p.R267P 17:7673820-7673820 30
49 COSM87898578 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.733G>A p.G245S 17:7674230-7674230 30
50 COSM87906003 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.503A>C p.H168P 17:7675109-7675109 30

Copy number variations for Thyroid Gland Anaplastic Carcinoma from CNVD:

7 (show all 18)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 18562 1 146514610 148102224 Gain Anaplastic thyroid cancer
2 57418 11 63321142 66212707 Gain CCND1 Anaplastic thyroid cancer
3 68082 12 47384342 48639263 Gain Anaplastic thyroid cancer
4 78984 13 61113549 63481793 Loss Anaplastic thyroid cancer
5 99673 16 28082639 28922556 Gain Anaplastic thyroid cancer
6 114238 17 45949240 46466966 Gain Anaplastic thyroid cancer
7 124653 19 11950033 12150103 Gain Anaplastic thyroid cancer
8 128382 19 40542097 41211643 Gain Anaplastic thyroid cancer
9 152529 20 31497814 33184582 Gain Anaplastic thyroid cancer
10 153944 20 41887694 44153298 Gain UBCH10 Anaplastic thyroid cancer
11 161614 22 19538297 19939137 Gain Anaplastic thyroid cancer
12 164302 22 36003989 36444264 Gain Anaplastic thyroid cancer
13 171639 3 170900000 182700000 Copy number PIK3CA Anaplastic thyroid cancer
14 182004 4 132076562 133123563 Loss Anaplastic thyroid cancer
15 188265 4 61317501 66095641 Loss Anaplastic thyroid cancer
16 211600 6 33165527 33494594 Gain Anaplastic thyroid cancer
17 225370 7 45400000 54000000 Amplification EGFR Anaplastic thyroid cancer
18 227803 7 72035816 72259198 Gain Anaplastic thyroid cancer
Sources

Expression for Thyroid Gland Anaplastic Carcinoma

About this section
Search GEO for disease gene expression data for Thyroid Gland Anaplastic Carcinoma.
Sources

Pathways for Thyroid Gland Anaplastic Carcinoma

About this section

Pathways related to Thyroid Gland Anaplastic Carcinoma according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Aldosterone synthesis and secretion 36
Show member pathways
 12.81 TSHR TPO TG PAX8 CDKN1A BRAF
2
Development HGF signaling pathway 22
Show member pathways
 12.66 TP53 PTEN PIK3CA CDH1 BRAF
3
Gastric cancer 36
Show member pathways
 12.65 TP53 PTEN PIK3CA CDKN1A CDH1 BRAF
4
ErbB signaling pathway 36 1
Show member pathways
 12.56 TP53 PTEN PIK3CA CDKN1A BRAF
5
Glioma 36
Show member pathways
 12.55 TP53 PTEN PIK3CA CDKN1A CDH1 BRAF
6
Endometrial cancer 36
Show member pathways
 12.5 TP53 RET PTEN PIK3CA PAX8 CDKN1A
7
Development IGF-1 receptor signaling 22
Show member pathways
 12.34 TP53 PTEN PIK3CA CDKN1A
8
Human T-cell leukemia virus 1 infection 36
12.29 TP53 PTEN PIK3CA CDKN1A
9
Pathways in cancer 36
12.28 TP53 RET PTEN PIK3CA PAX8 CDKN1A
10
Translation Non-genomic (rapid) action of Androgen Receptor 22
Show member pathways
 12.26 TP53 PTEN PIK3CA CDKN1A
11
Proteoglycans in cancer 36
12.25 TP53 PIK3CA CDKN1A BRAF
12
DNA Damage Response 1
Show member pathways
 12.22 TP53 PTEN MIR19A MIR18A MIR17 CDKN1A
13
MAPK Signaling: Mitogens 64
Show member pathways
 12.16 TP53 PTEN PIK3CA CDKN1A BRAF
14
Colorectal Cancer Metastasis 63
12.13 TP53 CDKN1A CDH1 BRAF
15
Cellular senescence (KEGG) 36
12.09 TP53 PTEN PIK3CA CDKN1A
16
Integrated Breast Cancer Pathway 1
12.07 TP53 PTEN CDH1 BRAF
17
FoxO signaling pathway 36
Show member pathways
 12 PTEN PIK3CA CDKN1A BRAF
18
DNA Damage Response (only ATM dependent) 1
11.91 TP53 PTEN PIK3CA CDKN1A
19
Glioblastoma Multiforme 63
11.88 TP53 PTEN CDKN1A BRAF
20
Senescence and Autophagy in Cancer 1
11.85 TP53 PTEN CDKN1A BRAF
21
MicroRNAs in cancer 36
11.81 TP53 PTEN PIK3CA MIR34C MIR30D MIR30A
22
VEGF Pathway (Tocris) 60
Show member pathways
 11.76 RET PIK3CA BRAF
23
Small cell lung cancer 36
11.76 TP53 PTEN PIK3CA CDKN1A
24
Platinum drug resistance 36
11.69 TP53 PIK3CA CDKN1A
25
Pathways Affected in Adenoid Cystic Carcinoma 1
11.64 TP53 PTEN PIK3CA
26
Bladder cancer 36 1
11.62 TP53 CDKN1A CDH1 BRAF
27
Central carbon metabolism in cancer 36
11.58 TP53 RET PTEN PIK3CA
28
Parkinsons Disease Pathway 1
11.58 MIR34C MIR30A MIR19A MIR18A MIR17
29
Human Thyroid Stimulating Hormone (TSH) signaling pathway 1
11.54 TSHR PIK3CA PAX8 BRAF
30
Copper homeostasis 1
11.53 TP53 PTEN PIK3CA
31
miRNAs involved in DNA damage response 1
11.49 TP53 MIR34C CDKN1A
32
Integrated Cancer Pathway 1
11.44 TP53 PTEN CDKN1A
33
LncRNA-mediated mechanisms of therapeutic resistance 1
10.74 TP53 CDKN1A
34
Transcriptional activation of p53 responsive genes 65
Show member pathways
 10.55 TP53 CDKN1A
35
Thyroxine (Thyroid Hormone) Production 1
10.28 TSHR TPO TG
Sources

GO Terms for Thyroid Gland Anaplastic Carcinoma

About this section

Cellular components related to Thyroid Gland Anaplastic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 TPO TG MIR30D MIR30A MIR19A MIR18A
2 extracellular vesicle GO:1903561 9.26 MIR30D MIR30A MIR19A MIR17

Biological processes related to Thyroid Gland Anaplastic Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.93 MIR34C MIR30D MIR30A MIR19A MIR18A MIR17
2 negative regulation of apoptotic process GO:0043066 9.85 TP53 PTEN MIR30A MIR19A CDKN1A BRAF
3 response to drug GO:0042493 9.83 TP53 RET PTEN CDKN1A CDH1
4 positive regulation of gene expression GO:0010628 9.8 TP53 RET PTEN NKX2-1 MIR30A BRAF
5 response to organic substance GO:0010033 9.75 PTEN CDKN1A CDH1
6 cellular response to nerve growth factor stimulus GO:1990090 9.65 PTEN CALCA BRAF
7 endothelial cell migration GO:0043542 9.58 PTEN PIK3CA CALCA
8 replicative senescence GO:0090399 9.57 TP53 CDKN1A
9 response to arsenic-containing substance GO:0046685 9.56 PTEN CDKN1A
10 hormone biosynthetic process GO:0042446 9.55 TPO TG
11 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.54 MIR34C MIR17
12 positive regulation of B cell receptor signaling pathway GO:0050861 9.52 MIR19A MIR18A
13 regulation of axon regeneration GO:0048679 9.51 PTEN BRAF
14 signal transduction by p53 class mediator GO:0072331 9.49 TP53 CDKN1A
15 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.33 TP53 PTEN MIR17
16 thyroid-stimulating hormone signaling pathway GO:0038194 9.26 TSHR PAX8
17 negative regulation of sprouting angiogenesis GO:1903671 9.26 MIR34C MIR19A MIR18A MIR17
18 thyroid gland development GO:0030878 8.92 TG PAX8 NKX2-1 BRAF

Molecular functions related to Thyroid Gland Anaplastic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 thyroid-stimulating hormone receptor activity GO:0004996 8.62 TSHR PAX8
Sources

Sources for Thyroid Gland Anaplastic Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....